The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
#EHA2024: Aggressive B-NHL
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to Aggressive B-NHL, here.
CONGRESS #EHA2024 | Jeremy Abramson reports 3-yr follow-up data of the TRANSFORM trial of liso-cel in pts with R/R LBCL. mFU= 33.9 mo, ORR=87%, CR=74%, 36 mo PFS=50.9%, 36 mo OS=62.8% - superior to SoC. Safety was consistent with interim and primary analyses. No grade 4/5 CRS… pic.twitter.com/4voVaYLr7o
— Lymphoma Hub (@lymphomahub) June 16, 2024
CONGRESS #EHA2024 | Jeremy Abramson reports 3-yr follow-up data of the TRANSFORM trial of liso-cel in pts with R/R LBCL. mFU= 33.9 mo, ORR=87%, CR=74%, 36 mo PFS=50.9%, 36 mo OS=62.8% - superior to SoC. Safety was consistent with interim and primary analyses. No grade 4/5 CRS… pic.twitter.com/4voVaYLr7o
— Lymphoma Hub (@lymphomahub) June 16, 2024
CONGRESS #EHA2024 | Poster | Mingci Cai at Shanghai institute of hematology reports phase 2 study of tazemetostat plus amdizalisib in pts with R/R lymphomas. N=21. Azemetostat plus amdizalisib shown promising efficacy and safety in R/R lymphoma, particularly in PTCL and DLBCL,… pic.twitter.com/rInM2KkFCb
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS | #EHA2024 | David Lavie, Hadassah Medical Center presents first data of SC administration of epcoritamab + POLA-R-CHP for the treatment of first-line DLBCL.
— Lymphoma Hub (@lymphomahub) June 15, 2024
ORR 100%, CR 88.6%, median duration of CR not reached, Grade 3/4 TEAE 76%, neutropenia 65% (all GR 3/4), CRS… pic.twitter.com/hCHbwz6m8o
CONGRESS | #EHA2024 | Sirpa Leppä @helsinkiuni shares data on biomarker-adapted treatment in high-risk LBCL. All versus biol high-risk patients 5-year OS 89% and 88%, PFS 83% and 77%, DA-EPOCH-R regimens may improve outcomes in biol-HR patients.#lymsm pic.twitter.com/1HPxEbDLf7
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS | #EHA2024 | Marcel Nijland presents the final analysis from the HOVON 151 clinical trial of atezolizumab consolidation in high-risk DLBCL. 2-year DFS 87.9%, Grade 3/4 immune-related AEs 4.5%, infections were the most common toxicity, with nearly 50% COVID-19,… pic.twitter.com/vgQkXiy6du
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS | #EHA2024
— Lymphoma Hub (@lymphomahub) June 15, 2024
Marie José Kersten @UvA_Amsterdam @amsterdamumc presents findings from the ongoing phase I/II ATALANTA-1 trial of GLPG5101, showing the feasibility of decentralized CAR T-cell manufacturing in 33 patients with R/R NHL, with a short vein-to-vein time and no… pic.twitter.com/ihWzxHrD0S
CONGRESS | #EHA2024
— Lymphoma Hub (@lymphomahub) June 15, 2024
Jean Galtier @CHUBordeaux reports on 55 patients with R/R PMBCL treated with axi-cel in the French DESCAR-T registry (CARTHYM study).
▪️ Strong efficacy seen (ORR=91%, CR=80%)
▪️ At median follow-up of 23 months, estimated 2-yr PFS=68.7%; median PFS not… pic.twitter.com/A5J1B4rz24
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
